Sagiv-Barfi et al. [89] sought to investigate the efficacy of therapy composed of ibrutinib (Pharmacyclics LLC, Sunnyvale, CA, USA) and anti-PD-L1 antibodies (BioXcell, Lebanon, NH, USA) on several different cell lines, including the 4T1 cell line—a triple-negative breast cancer cell line. Here, CD274 is linked to triple-negative breast carcinoma.